GlassScriptPhysician profile
Asit Patnaik
NPI 1831280650
$13,237.22
in general payments reported to CMS, 2019-2025
37 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $1,681 · 2021: $2,093 · 2022: $2,436 · 2023: $1,878 · 2024: $1,440 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,016 · Education: $13.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,015.84 |
| Education | $13.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $1,603.91 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Astrazeneca Pharmaceuticals LP | $1,558.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,233.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,170.74 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,097.18 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $852.88 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $621.04 | 2019-2023 | |
| Pfizer INC. | $615.10 | 2019-2025 | |
| Abbvie INC. | $505.47 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $467.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $461.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $418.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $291.57 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $265.33 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $241.91 | 2022-2024 | Quviviq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asit Patnaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.